Peter H Wiernik
Overview
Explore the profile of Peter H Wiernik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
4058
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiley Z, Mahapatra S, Agarwal G, Baer S, Baer S, Bukhari S, et al.
J Investig Med
. 2025 Mar;
:10815589251327504.
PMID: 40022538
No abstract available.
2.
Wiernik P, Blakley M, Dutcher J
J Investig Med
. 2024 Jun;
72(8):842-847.
PMID: 38869159
Forty-one families with multiple cases of de novo acute myeloid leukemia (AML), B-cell acute lymphocytic leukemia (B-ALL), or both are presented. The families were randomly collected from physicians, genetic counselors,...
3.
Wiernik P, Dutcher J
J Investig Med
. 2023 Oct;
72(1):26-31.
PMID: 37864488
Although reports of familial clustering of hematologic malignancies have appeared for decades, the cause(s) of this uncommon occurrence is still not completely understood. Most modern investigations, however, support a genetic...
4.
Wiernik P
Br J Haematol
. 2022 Nov;
200(2):126-127.
PMID: 36342482
Mitochondrial biology may influence the outcome of therapy for acute promyelocytic leukemia if arsenic trioxide is not part of the treatment. Inclusion of arsenic trioxide in the treatment regimen may...
5.
Rashkovan M, Albero R, Gianni F, Perez-Duran P, Miller H, Mackey A, et al.
Cancer Discov
. 2021 Oct;
12(3):856-871.
PMID: 34711640
Significance: Overtly distinct cell metabolic pathways operate in ETP- and T-ALL pointing to specific metabolic vulnerabilities. Inhibition of mevalonate biosynthesis selectively blocks oncogenic AKT-MYC signaling in ETP-ALL and suppresses leukemia...
6.
Ganzel C, Lee J, Fernandez H, Paietta E, Luger S, Lazarus H, et al.
Blood Adv
. 2021 Oct;
5(22):4560-4568.
PMID: 34597373
Central nervous system (CNS) involvement in patients with newly diagnosed acute myeloid leukemia (AML) is rare, and systematic data regarding outcome are scarce. This retrospective study summarized data from 11...
7.
Wiernik P, Sun Z, Cripe L, Rowe J, Fernandez H, Luger S, et al.
Br J Haematol
. 2021 Jun;
194(2):309-318.
PMID: 34145576
There are conflicting reports in the literature suggesting that one gender or the other has a better survival with acute myeloid leukaemia (AML). The present study was done in an...
8.
Paietta E, Roberts K, Wang V, Gu Z, Buck G, Pei D, et al.
Blood
. 2021 Apr;
138(11):948-958.
PMID: 33895809
Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1- B-ALL (aged...
9.
Clark J, Curti B, Davis E, Kaufman H, Amin A, Alva A, et al.
J Investig Med
. 2021 Feb;
PMID: 33542072
High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who...
10.
Ganzel C, Wang X, Rowe J, Richards S, Buck G, Marks D, et al.
Br J Haematol
. 2020 Mar;
191(1):37-43.
PMID: 32220069
Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics...